Follow The Filings

PRAX Praxis Precision Medicines

Health Care, filed as PRAXIS PRECISION MEDICINES I (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.0%
  • $2.4M
  • 1 reduce

In 2026 Q2 Polen Capital Management trimmed Praxis Precision Medicines.

Who owns this now

Largest portfolio weights among holders, up to 0.0% (Polen Capital Management). Not free-float ownership.

  1. Polen Capital Management Reduce 0.02%

Who owns PRAX

Sorted by value, long equity only, as of 2026 Q2.

History
Polen Capital Management 0.02% Reduce −27.8% 7,252 $2.4M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by PRAX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All PRAX insider trades
  • None no insider bought on the open market
  • $7.5M sold by 2 insiders outside a trading plan
  • $3.6M sold by 1 insider under 10b5-1 plans
  1. Jill DeSimone Director
    Planned sale
    $3.6M 11,600 shares at $311.32 83% of stake
    Traded Jun 24 Filed Jun 26
    ↗
  2. Alex Nemiroff General Counsel and Secretary
    Sale
    $4.9M 25,130 shares at $193.09 55% of stake
    Traded Nov 20, 2025 Filed Nov 21, 2025
    ↗
  3. Lauren Mastrocola Principal Accounting Officer
    Sale
    $2.6M 13,600 shares at $192.08 57% of stake
    Traded Nov 20, 2025 Filed Nov 21, 2025
    ↗
  4. Adage Capital Management, L.P. 10% owner, +2 joint filers
    Sale
    $33.2M 313,910 shares at $105.76
    Traded Oct 16, 2025 Filed Oct 17, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 23 stock grants, 14 option exercises, 13 share withholdings for taxes, and 3 gifts.

Congress

1 member of Congress traded PRAX in the last three years: 2 buys and 0 sales.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Sep 29 filed Oct 12
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jul 30 filed Sep 4

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01 Filing Doc
8-K 4.01,9.01 Filing Doc
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
8-K 5.07 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.45M $8.55M $0M
Net income -$123.28M -$182.82M -$303.27M
Net margin * -5037.9% -2137.5% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $84.88M $404.37M $610.91M
Total non-current assets * $3.07M $78.74M $327M
Total assets $87.95M $483.11M $937.91M
Total current liabilities $15.75M $37.55M $59.77M
Total non-current liabilities * $2.53M $0.11M $0M
Total equity $64.47M $229.68M $878.14M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$111.14M -$131.76M -$249.07M
Cash from investing $38.95M -$248.49M -$311.15M
Cash from financing $91.87M $514.32M $702.17M
Net change in cash $19.68M $134.07M $141.96M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.